Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
复制标题
叶酸受体阳性循环肿瘤细胞对一线化疗小细胞肺癌患者的预测和预后价值
DOI：
10.18632/oncotarget.17039
复制
发表时间：
2017-07-25
期刊：
影响因子：
--
通讯作者：
Zhou C
中科院分区：
文献类型：
--
作者：
Shen J;Zhao J;Jiang T;Li X;Zhao C;Su C;Zhou C
评估叶酸受体（FR）阳性循环肿瘤细胞（CTCs）在接受一线化疗的小细胞肺癌（SCLC）患者中的预测和预后意义。纳入符合条件的初治、不可切除的SCLC患者，并采集血液样本。在基线、两个化疗周期后以及疾病进展时，使用配体靶向聚合酶链反应（LT - PCR）对CTCs进行计数。共纳入80例患者，其中67例（83.8%）在基线时CTC计数为阳性（CTCs≥8.7 FU/3mL）。部分缓解（PR）患者的基线CTC计数显著高于疾病进展（PD）患者（P = 0.0365）。两个化疗周期后CTC计数明显减少与PR显著相关（P = 0.0380），而与疾病稳定（SD）无关（P = 0.4934）。在CTC计数阳性组中，CTC水平相对较低的患者无进展生存期（PFS）和总生存期（OS）显著长于CTC水平较高的患者（PFS：9.1个月对6.9个月，P = 0.0458；OS：11.1个月对8.6个月，P = 0.056）。在多因素分析中，远处转移（HR = 1.466，P = 0.021）和相对较低的CTC水平（HR = 0.656，P = 0.049）是接受一线化疗的SCLC患者的独立预测因素。本研究结果表明，基线CTC计数可作为接受一线化疗的SCLC患者有价值的预测和预后生物标志物。两个化疗周期后CTC计数的减少是SCLC化疗反应的一个潜在预测指标。
To assess the predictive and prognostic significance of folate receptor (FR)-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) received first-line chemotherapy. Eligible patients with chemotherapy-naïve, unresectable SCLC were enrolled and blood samples were collected. CTCs were enumerated using ligand-targeted polymerase chain reaction (LT-PCR) at baseline, after two cycles of chemotherapy regimen and on disease progression. In total, 80 patients were enrolled and 67 (83.8%) had positive CTC count at baseline (CTCs ≥ 8.7 FU/3mL). The baseline CTC counts in patients with partial response (PR) were significantly higher than those with progression disease (PD) (P = 0.0365). An obvious reduction of CTC enumeration after two cycles of chemotherapy was significantly correlated with PR (P = 0.0380), instead of SD (P = 0.4934). Among positive CTC count group, patients with relative low CTC level had significantly longer progression-free survival (PFS) and overall survival (OS) than those with high CTC level (PFS: 9.1 vs 6.9 months, P = 0.0458; OS: 11.1 vs 8.6 months, P = 0.056). In multivariate analysis, distant metastases (HR = 1.466, P = 0.021) and relative low CTC level (HR = 0.656, P = 0.049) were the independent predictive factors for patients with SCLC received first-line chemotherapy. The present results demonstrated that baseline CTC counts could be the valuable predictive and prognostic biomarker for patients with SCLC received first-line chemotherapy. The reduction of CTC enumeration after two cycles of chemotherapy was a potential predictor of chemotherapeutic response in SCLC.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
影响因子：
4.2
作者：
Chudziak, Jakub;Burt, Deborah J.;Brady, Ged
通讯作者：
Brady, Ged
影响因子：
3.8
作者：
Gorges TM;Tinhofer I;Drosch M;Röse L;Zollner TM;Krahn T;von Ahsen O
通讯作者：
von Ahsen O
影响因子：
50.5
作者：
Hiltermann, T. J. N.;Pore, M. M.;Groen, H. J. M.
通讯作者：
Groen, H. J. M.
影响因子：
45.3
作者：
Cohen, Steven J.;Punt, Cornelis J. A.;Meropol, Neal J.
通讯作者：
Meropol, Neal J.